- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02236169
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
September 9, 2014 updated by: Boehringer Ingelheim
An Open-Label, Crossover, Pharmacokinetic Trial to Determine the Comparability of 84 µg Ipratropium Bromide HFA-134a Inhalation Aerosol to 84 µg ATROVENT® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study was to determine the pharmacokinetic comparability of 84 µg ipratropium bromide HFA-134a inhalation aerosol and 84 µg ATROVENT® CFC Inhalation Aerosol in COPD patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All patients must have a diagnosis of COPD and must meet the following spirometric criteria:
Patients must have a stable, moderate to severe airway obstruction with an Forced Expiratory Volume in one second (FEV1) <=65% of predicted normal and FEV1 <=70% of Forced vital capacity (FVC)
- Males: Predicted Normal FEV1 = 0.093 (height in inches)-0.032 (age)-1.343
- Females: Predicted Normal FEV1 = 0.085 (height in inches)-0.025(age)-1.692
- Male or female age 40 years or older
- Patients must have a smoking history of more than 10 pack-years. A pack-year is defined as the equivalent of smoking one pack of cigarettes (20 cigarettes) per day for a year
- Patients must be able to satisfactorily administer the medication, perform pulmonary function tests (PFTs) and maintain records during the study period as required in the protocol
- All patients must sign an Informed Consent Form prior to participation in the trial (i.e., prior to pre-study washout of their usual pulmonary medications and prior to fasting for laboratory tests)
Exclusion Criteria:
- Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease with may influence the results of the study or patients ability to participate in the study
- Patients with clinically relevant baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion the patient is excluded
- All patients with serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L, serum glutamic pyruvic transaminase (SGPT) >80 IU/L, bilirubin >2.0 mg/dl, or creatinine >2.0 mg/dl will be excluded regardless of the clinical condition. Repeat laboratory evaluation will be not be conducted in these patients
- Patients with a history of asthma, allergic rhinitis or atopy or who have a blood eosinophil count above 600/mm3. A repeat eosinophil count will be not be conducted in these patients
- Patients with a recent (i.e., one year or less) history of myocardial infarction
- Patients with a recent history (i.e., three years or less) of cardiac failure, patients with cardiac arrhythmia requiring therapy, patients receiving any systemic beta-blockers and patients on chronic daytime oxygen therapy
- Patients with known active tuberculosis
- Patients with a history of cancer within the last 5 years. Patients with treated basal cell carcinoma are allowed
- Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
- Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reason should be evaluated per exclusion criterion No.1
- Patients with an upper respiratory tract infection or COPD exacerbation in the 6 weeks prior to the screening visit (Visit 1) or during the baseline period
- Patients with known hypersensitivity to anticholinergic drugs
- Patients with known symptomatic prostatic hypertrophy or bladder-neck obstruction
- Patients with known narrow-angle glaucoma
- Patients who are on cromolyn sodium or nedocromil sodium
- Patients who are on antihistamines
- Pregnant or nursing women and women of childbearing potential not using a medically approved means of contraception (e.g., oral contraceptive, intrauterine devices, diaphragm or Norplant®)
- Patients who have taken an investigational drug within 1 month or 6 half-lives (whichever is longer) of the drug prior to the screening visit or patients currently enrolled in another research study
- Patients with a history of and/or active alcohol or drug abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ipratropium bromide
|
|
Active Comparator: ATROVENT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Amount of unchanged ipratropium excreted in the urine from 0 to 24 h after a single dose
Time Frame: Up to 24 hours (h) after single drug administration
|
Up to 24 hours (h) after single drug administration
|
Amount of unchanged ipratropium excreted in the urine within 1 hour at steady state
Time Frame: 1h after drug administration
|
1h after drug administration
|
Amount of unchanged ipratropium excreted in the urine over the 6 h dosing interval at steady state
Time Frame: up to 6 h after drug administration
|
up to 6 h after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma ipratropium concentration time curve at different time points
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Peak plasma ipratropium concentration at different time points
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Trough plasma ipratropium concentration at different time points
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Time to peak plasma ipratropium concentrations at steady state
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Degree of fluctuation (DF) of the plasma ipratropium concentrations
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Area under the plasma ipratropium concentration time curve
Time Frame: Day 1 after first drug administration
|
Day 1 after first drug administration
|
Peak plasma ipratropium concentration
Time Frame: Day 1 after first drug administration
|
Day 1 after first drug administration
|
Number of patients with adverse events
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Changes from baseline in pulse rate and blood pressure
Time Frame: Baseline, day 23 day after first drug administration
|
Baseline, day 23 day after first drug administration
|
Number of patients with clinical significant findings in laboratory tests
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Number of patients with clinical significant findings in physical examination
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Number of patients with clinical significant findings in electrocardiogram (ECG)
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Changes from test-day baseline in pulse rate and blood pressure
Time Frame: Up to 23 days after first drug administration
|
Up to 23 days after first drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2000
Primary Completion (Actual)
April 1, 2001
Study Registration Dates
First Submitted
September 9, 2014
First Submitted That Met QC Criteria
September 9, 2014
First Posted (Estimate)
September 10, 2014
Study Record Updates
Last Update Posted (Estimate)
September 10, 2014
Last Update Submitted That Met QC Criteria
September 9, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Respiratory Aspiration
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Anesthetics
- Anticonvulsants
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Bromides
- Ipratropium
- Norflurane
Other Study ID Numbers
- 244.2480
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Ipratropium bromide HFA-134a inhalation aerosol
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimTerminatedPulmonary Disease, Chronic Obstructive
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
University of SaskatchewanRoyal University Hospital FoundationCompleted
-
Pearl Therapeutics, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Boehringer IngelheimCompleted
-
Amphastar Pharmaceuticals, Inc.CompletedAsthma | Shortness of Breath | Wheezing | BronchospasmUnited States
-
Amphastar Pharmaceuticals, Inc.Terminated
-
Amphastar Pharmaceuticals, Inc.Completed
-
Amphastar Pharmaceuticals, Inc.Terminated